Thomas Prebet, MD, PhD

After completing his doctorate in medical hematology and oncology in Lyon, France, Dr. Prebet joined Institut Paoli-Calmettes in Marseille, France and completed a fellowship in Johns Hopkins University (Baltimore, MA, USA) as a Fullbright alumni. Dr. Prebet is currently the director of the inpatient hematology unit and the medical director of the hematology division of Yale Clinical Trial Office. He is the associate director of the myeloid malignancies program in the hematology department of the Yale Cancer Center, New haven, CT. He is developing myeloid malignancies clinical trials and translational works for advanced phase acute myeloid leukemia and myelodysplastics syndromes. The current works gave the basis for defining demethylating agent failure outcome (Prebet JCO 2011, Hematologica 2012, British Journal of Hematology 2012, Blood Advance 2018), contributed to his knowledge of combinations therapies based on HDAC inhibitors (Prebet JCO 2014, Prebet Leuk Res 2014) and gave the first insights on the implication of Wnt non canonical pathway in acute myeloid leukemia (Prebet Blood 2011). Dr Prebet is the coordinating investigator of several clinical trials for myelodysplastic syndromes and acute leukemia patients and contributed to 110 peer reviewed manuscript.